Adverse Events Attributable to Nocebo in Randomized Controlled Drug Trials in Fibromyalgia Syndrome and Painful Diabetic Peripheral Neuropathy: Systematic Review: Erratum

Clinical Journal of Pain:
doi: 10.1097/AJP.0000000000000073
Erratum

    In the June 2012 issue of The Clinical Journal of Pain in the article by Häuser et al, “Adverse Events Attributable to Nocebo in Randomized Controlled Drug Trials in Fibromyalgia Syndrome and Painful Diabetic Peripheral Neuropathy: Systematic Review,” some data were erroneous. In the following sentence of the ABSTRACT and DISCUSSION/Summary of main results, “Nocebo effects accounted for 72.0% of the drop outs in true drug groups in FMS” is incorrect. The correct data are as follows (see data in the results section): Nocebo effects accounted for 58.9% of the drop outs in true drug groups in FMS (DPN).

    Back to Top | Article Outline

    REFERENCE

    Häuser W, Bartram C, Bartram-Wunn E, et al..Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review. Clin J Pain. 2012;28(5):437–451.
    © 2014 by Lippincott Williams & Wilkins